What makes the drug unique is that it is inactive upon injection and activates in the presence of a localized site with excessive inflammation, according to the paper, published in the Journal of Immunology. A protein molecule keeps the drug inactive until it encounters inflammatory enzymes.
“This development is important because inhibition of inflammation in a non-specific manner reduces the natural ability to fight infections and is a common side effect of anti-inflammatory biologic therapeutic,” said Peleg Rider, PhD, researcher in BGU’s department of clinical biochemistry and pharmacology.
More articles on infection control:
Most healthcare workers improperly remove protective equipment
10 interesting developments in hand hygiene
Sleep apnea unrecognized in 87% of at-risk patients
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.